
Hospital-Acquired Bacterial Pneumonia and Ventilator- Associated Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**June 2020
Clinical/Antimicrobial**

Hospital-Acquired Bacterial Pneumonia and Ventilator- Associated Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry

Additional copies are available from:

*Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002*

*Phone 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: druginfo@fda.hhs.gov
<https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>*

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**June 2020
Clinical/Antimicrobial**

TABLE OF CONTENTS

- I. INTRODUCTION.....1**
- II. BACKGROUND1**
- III. DEVELOPMENT PROGRAM.....2**
 - A. General Considerations2**
 - 1. Nonclinical Development Considerations.....2*
 - 2. Drug Development Population.....2*
 - 3. Efficacy Considerations3*
 - 4. Safety Considerations.....3*
 - 5. Clinical Microbiology Considerations.....3*
 - B. Specific Efficacy Trial Considerations4**
 - 1. Trial Design.....4*
 - 2. Trial Population4*
 - 3. Inclusion and Exclusion Criteria.....4*
 - a. Inclusion criteria.....4
 - b. Exclusion criteria.....5
 - 4. Randomization and Blinding.....5*
 - 5. Specific Populations6*
 - 6. Dose Selection.....6*
 - 7. Choice of Comparators and Concomitant Antibacterial Drugs.....6*
 - 8. Prior Antibacterial Drug Therapy.....7*
 - 9. Efficacy Endpoints.....7*
 - a. Primary endpoints.....7
 - b. Secondary endpoints.....8
 - 10. Trial Procedures and Timing of Assessments.....8*
 - a. Entry visit8
 - b. On-therapy and end-of-therapy visits.....8
 - c. Visits after completion of therapy8
 - 11. Statistical Considerations8*
 - a. Analysis populations.....9
 - b. Noninferiority margins9
 - c. Sample size considerations.....9
 - C. Other Considerations10**
 - 1. Pharmacokinetic/Pharmacodynamic Considerations.....10*
 - 2. Labeling Considerations10*
- REFERENCES.....11**
- APPENDIX.....13**

1 **Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated**
2 **Bacterial Pneumonia: Developing Drugs for Treatment**
3 **Guidance for Industry¹**
4
5
6

7
8 This guidance represents the current thinking of the Food and Drug Administration (FDA or
9 Agency) on this topic. It does not establish any rights for any person and is not binding on FDA
10 or the public. You can use an alternative approach if it satisfies the requirements of the
11 applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff
12 responsible for this guidance as listed on the title page.
13

14
15
16
17 **I. INTRODUCTION**
18

19 The purpose of this guidance is to assist sponsors and investigators in the clinical development of
20 drugs for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-
21 associated bacterial pneumonia (VABP).² Specifically, this guidance addresses the FDA's
22 current thinking about the overall development program and clinical trial designs for drugs to
23 support an indication for treatment of HABP/VABP.
24

25 This guidance does not discuss the general issues of statistical analysis or clinical trial design.
26 Those topics are addressed in the ICH guidances for industry *E9 Statistical Principles for*
27 *Clinical Trials* (September 1998) and *E10 Choice of Control Group and Related Issues in*
28 *Clinical Trials* (May 2001), respectively.³
29

30 In general, FDA's guidance documents do not establish legally enforceable responsibilities.
31 Instead, guidances describe the Agency's current thinking on a topic and should be viewed only
32 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
33 the word *should* in Agency guidances means that something is suggested or recommended, but
34 not required.
35

36
37 **II. BACKGROUND**

¹ This guidance has been prepared by the Division of Anti-Infectives in the Center for Drug Evaluation and Research at the Food and Drug Administration.

² For the purposes of this guidance, all references to *drugs* include both human drugs and therapeutic biological products unless otherwise specified.

³ We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

Contains Nonbinding Recommendations

38
39 HABP/VABP occurs in hospitalized patients and in patients who have been recently discharged
40 from the hospital. A hospital stay of 48 hours or more places patients at risk for infection with a
41 variety of organisms, including gram-positive bacteria such as methicillin-resistant
42 *Staphylococcus aureus* and gram-negative bacteria such as *Klebsiella pneumoniae*, *Pseudomonas*
43 *aeruginosa*, and *Acinetobacter* species.

44

45

46 **III. DEVELOPMENT PROGRAM**

47

48 **A. General Considerations**

49

50 *1. Nonclinical Development Considerations*

51

52 In addition to the expected nonclinical pharmacology/toxicology studies (see Section III. C. 1,
53 Pharmacokinetic/Pharmacodynamic Considerations), sponsors should provide nonclinical data
54 from in vitro studies and in vivo animal studies⁴ demonstrating activity against one or more of
55 the commonly implicated pathogens for HABP/VABP.⁵

56

57 *2. Drug Development Population*

58

59 HABP is an acute infection of the pulmonary parenchyma that is associated with clinical signs
60 and symptoms such as fever or hypothermia, chills, rigors, cough, purulent sputum production,
61 chest pain, or dyspnea, accompanied by the presence of a new or progressive infiltrate on a chest
62 radiograph in a patient hospitalized for more than 48 hours or developing within 7 days after
63 discharge from a hospital.⁶ Patients with HABP may or may not require intubation and
64 mechanical ventilation.

65

66 VABP is an acute infection of the pulmonary parenchyma that is associated with clinical signs
67 and symptoms such as fever or hypothermia, chills, rigors, purulent respiratory secretions, and
68 increased oxygen requirements. These signs and symptoms are in addition to laboratory
69 abnormalities such as leukocytosis accompanied by the presence of a new or progressive
70 infiltrate on a chest radiograph in a patient on mechanical ventilation for a minimum of 48 hours.

71

⁴ We support the principles of the 3Rs (reduce/refine/replace) for animal use in testing when feasible. FDA encourages sponsors to consult with review divisions when considering a nonanimal testing method believed to be suitable, adequate, validated, and feasible. FDA will consider if the alternative method could be assessed for equivalency to an animal test method.

⁵ See the guidelines from the American Thoracic Society and the Infectious Diseases Society of America (Kalil et al. 2016), or other relevant publications, for descriptions of bacterial pathogens commonly identified in patients with HABP/VABP.

⁶ Oral and nasotracheal bacterial flora may not return to normal flora within 4 to 6 weeks or longer after hospitalization.

Contains Nonbinding Recommendations

72 3. *Efficacy Considerations*

73
74 A showing of superiority or noninferiority, using an acceptable noninferiority margin, to a
75 control drug in the treatment of HABP/VABP is readily interpretable as evidence of
76 effectiveness (see the Appendix).⁷

77
78 The Agency generally expects sponsors to conduct two adequate and well-controlled trials in
79 CABP to establish substantial evidence of effectiveness. Alternatively, a single adequate and
80 well-controlled trial in HABP/VABP with confirmatory evidence (e.g., the results of a trial in
81 another infectious disease indication) can provide substantial evidence of effectiveness.⁸
82 Sponsors should discuss with the FDA the confirmatory evidence that would be used to support
83 the efficacy findings from a single trial in HABP/VABP.

84 4. *Safety Considerations*

85
86
87 If the same or greater dose and treatment duration for HABP/VABP were used in clinical trials
88 for other infectious disease indications, safety data from these indications can be used to support
89 safety for HABP/VABP. Sponsors should discuss with the FDA the appropriate size of the
90 premarketing safety database during clinical development.

91 5. *Clinical Microbiology Considerations*

92
93
94 An adequate sputum specimen should be processed by a laboratory according to recognized
95 methods for Gram stain, culture, and in vitro antibacterial susceptibility testing.⁹

96
97 Use of rapid diagnostic or nonculture tests may help identify a patient for enrollment in an
98 HABP/VABP trial. If the tests being used are not FDA cleared, sponsors should provide
99 sufficient information about the performance characteristics of the tests determined from
100 analytical validation studies.

101
102 The clinical trial of an antibacterial drug also may provide an opportunity to develop and
103 evaluate a new diagnostic test. Sponsors interested in using a clinical trial in patients with
104 HABP/VABP as a means to also evaluate a diagnostic test are encouraged to discuss this with
105 the Agency.

⁷ See section 505(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

⁸ See the draft guidance for industry *Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products* (December 2019). When final, this guidance will represent the FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

⁹ Standard methods for in vitro susceptibility testing are developed by organizations such as the Clinical and Laboratory Standards Institute; see also the American Society for Microbiology, 2011, *Manual of Clinical Microbiology*, 10th edition.

Contains Nonbinding Recommendations

107 **B. Specific Efficacy Trial Considerations**

108

109 *1. Trial Design*

110

111 HABP/VABP trials should be randomized and double-blind when possible, comparing the
112 investigational drug with an active control. In general, HABP/VABP trials will be designed as
113 noninferiority trials. Another trial design is the add-on superiority design, in which patients
114 receive either a placebo or an investigational drug added to standard-of-care antibacterial drug
115 therapy.

116

117 *2. Trial Population*

118

119 For an indication for the treatment of HABP/VABP, the trial population should consist of
120 patients who have HABP (regardless of mechanical ventilation) or VABP. The trial population
121 should include at a minimum approximately 50 percent of patients who are on mechanical
122 ventilation at enrollment (VABP/ventilated HABP). Sponsors interested in seeking an indication
123 for HABP only should discuss the trial design and trial population with the Agency.

124

125 The protocol can specify the use of a clinical severity scoring system to identify a trial
126 population consisting of patients who have a sufficient severity of illness to maintain assay
127 sensitivity for the all-cause mortality endpoint in a noninferiority trial (e.g., at least a 15 percent
128 mortality rate). An example of a clinical severity scoring system is the Acute Physiology and
129 Chronic Health Evaluation II.

130

131 *3. Inclusion and Exclusion Criteria*

132

133 *a. Inclusion criteria*

134

135 Patients should have at least one of the following clinical features:

136

137 • New onset or acute worsening pulmonary symptoms or signs, such as cough,
138 dyspnea, tachypnea (e.g., respiratory rate greater than 25 breaths per minute),
139 expectorated sputum production, or requirement for mechanical ventilation

140

141 • Hypoxemia

142

143 • Need for acute changes in the ventilator support system to enhance oxygenation, as
144 determined by worsening oxygenation or needed changes in the amount of positive
145 end-expiratory pressure

146

147 • New onset of suctioned respiratory secretions

148

149 In addition, patients should have at least one of the following signs/laboratory abnormalities:

150

151 • Documented fever (e.g., body temperature greater than or equal to 38°C)

152

Contains Nonbinding Recommendations

- 153 • Hypothermia (e.g., core body temperature less than or equal to 35°C)
- 154
- 155 • Total peripheral white blood cell count greater than or equal to 10,000 cells per cubic
- 156 millimeter (mm³)
- 157
- 158 • Leukopenia with total white blood cell count fewer than or equal to 4,500 cells per
- 159 mm³
- 160
- 161 • Greater than 15 percent immature neutrophils (e.g., bands) noted on peripheral blood
- 162 smear
- 163

Plus

- 166 • A chest radiograph showing the presence of a new or progressive infiltrate suggestive
- 167 of bacterial pneumonia
- 168

b. Exclusion criteria

169 The following patients should be excluded from HABP/VABP clinical trials:

- 171
- 172
- 173 • Patients who have known or suspected community-acquired bacterial pneumonia or
- 174 viral pneumonia
- 175
- 176 • Patients who have received effective antibacterial drug therapy for HABP/VABP for
- 177 a continuous duration of more than 24 hours during the previous 72 hours (see section
- 178 III. B. 8., Prior Antibacterial Drug Therapy)
- 179

4. *Randomization and Blinding*

180 The protocol should specify randomization of patients to treatment groups at enrollment.

181 Randomization strategies other than 1:1 (e.g., 2:1 or 3:1 randomization of investigational drug to

182 active control) could be considered in certain situations (e.g., to enhance the size of the safety

183 database of the investigational drug). To the extent possible, the trial should be double-blinded.

184 If there is a compelling reason for single-blind or open-label trial designs, sponsors should

185 discuss with the Agency efforts to minimize bias before initiating the trial.

186

187

188

189 Sponsors should consider methods to enhance the efficiency of the enrollment and randomization

190 processes and enable prompt administration of antibacterial drug therapy within the context of

191 the clinical trial, thus avoiding the potential confounding by effective antibacterial drug therapy

192 before enrollment (see section III. B. 8., Prior Antibacterial Drug Therapy). For example, it

193 often may be the case that few HABP/VABP patients are enrolled at each clinical center. In this

194 case, sponsors may consider randomizing centers rather than individual patients to simplify

195 enrollment, with appropriate adjustments to the statistical analysis plan and informed consent

196 procedures to accommodate cluster randomization. As another example, sponsors could give

197 hospitalized patients at risk for developing HABP/VABP informed consent in anticipation of

198 participating in a clinical trial if the patient develops HABP/VABP (Corneli et al. 2018).

Contains Nonbinding Recommendations

199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236

5. *Specific Populations*

The trials should include patients of both sexes, patients of all races, and geriatric patients.¹⁰ The FDA encourages sponsors to begin discussions about their pediatric formulation and clinical development plan early in development because pediatric studies are a required part of the overall drug development program and sponsors are required to submit pediatric study plans no later than 60 days after an end-of-phase 2 meeting.¹¹ Extrapolation of adult efficacy findings in HABP/VABP to pediatrics is generally acceptable. However, studies are typically needed to determine the appropriate dose and assess the safety of the drug in the pediatric population. Sponsors should evaluate the pharmacokinetic (PK) information of the drug in specific populations (e.g., geriatric patients, patients with renal or hepatic impairment) to determine whether dose adjustments are necessary.

6. *Dose Selection*

To choose the dose or doses to be evaluated in phase 3 clinical trials, sponsors should integrate the findings from nonclinical toxicology studies; animal models of infection; pharmacokinetics, safety, and tolerability information from phase 1 clinical trials; and safety and efficacy information from phase 2 dose-ranging clinical trials. Trials assessing drug penetration at the site of action (e.g., epithelial lining fluid) may be helpful in defining doses that achieve concentrations sufficient to exert an antibacterial effect.

For products with both intravenous and oral formulations, sponsors should collect PK data in earlier phase studies to select the appropriate oral dose for the intravenous-to-oral switch.

7. *Choice of Comparators and Concomitant Antibacterial Drugs*

The active comparator drug should reflect the current standard of care for the treatment of HABP/VABP. When evaluating the current standard of care, the FDA considers the recommendations by authoritative scientific bodies (e.g., American Thoracic Society, Infectious Diseases Society of America) based on clinical evidence and other reliable information that reflects current clinical practice.

Ideally, an investigational drug would have activity against most bacterial pathogens implicated in HABP/VABP and concomitant antibacterial drugs would not be necessary. However, investigational drugs with a narrow spectrum of antibacterial activity can be developed for the treatment of HABP/VABP. Because concomitant antibacterial drugs can confound the

¹⁰ See the ICH guidances for industry *E7 Studies in Support of Special Populations: Geriatrics* (August 1994) and *E7 Studies in Support of Special Populations: Geriatrics; Questions and Answers* (February 2012).

¹¹ See the Pediatric Research Equity Act (Public Law 108-155; section 505B(e)(2)(A) of the FD&C Act; 21 U.S.C. 355B) as amended by the Food and Drug Administration Safety and Innovation Act (Public Law 112-144). See also the draft guidance for industry *Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans* (March 2016). When final, this guidance will represent the FDA's current thinking on this topic.

Contains Nonbinding Recommendations

237 interpretation of treatment effect in a noninferiority trial, the protocol should specify any use of
238 concomitant antibacterial drugs that may be permitted for treating patients with HABP/VABP
239 and address the impact these concomitant drugs may have on study conclusions.
240

241 To the extent possible, the concomitant antibacterial drug should not have antibacterial activity
242 similar to the spectrum of activity of the investigational drug. After culture and in vitro
243 susceptibility testing results are available, if there is a defined level of clinical improvement,
244 sponsors should consider de-escalating concomitant therapy.¹² Whenever possible, treatment
245 should be completed as monotherapy with the investigational drug in patients randomized to the
246 investigational drug group.
247

248 8. *Prior Antibacterial Drug Therapy*

249
250 Ideally, patients enrolled in an HABP/VABP clinical trial would not have received prior
251 antibacterial drug therapy. Prior antibacterial drug therapy can have important consequences for
252 a clinical trial. Specifically, prior antibacterial drug therapy could obscure true treatment
253 differences between an investigational drug and the control drug, introducing bias toward a
254 finding of no difference between treatment groups (i.e., a bias toward a finding of noninferiority;
255 see, for example, Pertel et al. 2008). However, excluding patients who have received prior
256 antibacterial drug therapy also could have adverse consequences. Specifically, certain trial sites
257 may decline to participate in the clinical trial because of concerns that trial treatment would not
258 represent standard of care and would place patients at risk.
259

260 A pragmatic approach to these concerns is to (1) encourage prompt enrollment procedures (e.g.,
261 anticipatory informed consent offered to patients at risk for developing HABP/VABP) so that
262 patients can receive the clinical trial treatment initially, with no need for other antibacterial drug
263 therapy; and (2) allow enrollment of patients who have received no more than 24 hours of
264 therapy before enrollment. Patients who have objective documentation of clinical failure while
265 receiving any duration of prior antibacterial drug therapy for treatment of HABP/VABP can be
266 enrolled.
267

268 9. *Efficacy Endpoints*

269 a. Primary endpoints

270 Sponsors should select one of the following two primary efficacy endpoints for clinical trials:
271

- 272 • A primary endpoint based on survival: all-cause mortality can be evaluated at a fixed
273 time point at any time between day 14 and day 28 (see the Appendix).
- 274 • A primary endpoint based on survival and no disease-related complications: all-cause
275 mortality or disease-related complications (e.g., development of empyema, onset of acute
276 respiratory distress syndrome, sepsis syndrome, other complications) can be evaluated at
277

¹² For example, see the recommendations for *de-escalation* of the initial empirical antibacterial drug therapy based on the culture results and in vitro susceptibility testing in the setting of clinical improvement at 48 to 72 hours (American Thoracic Society 2005).

Contains Nonbinding Recommendations

280 a fixed time point at any time between day 14 and day 28. Sponsors should discuss with
281 the Agency the disease-related complications before initiating the trial.

282
283 In general, the primary efficacy analysis should be based on a comparison of the proportions of
284 patients achieving the primary endpoint at a fixed time point from randomization.

285
286 b. Secondary endpoints

287
288 Secondary endpoints can include the following: (1) an assessment of resolution of signs and
289 symptoms of HABP/VABP at approximately 7 to 14 days after the completion of antibacterial
290 drug therapy, (2) days spent in the hospital, and (3) days spent on mechanical ventilation (for
291 VABP and ventilated-HABP patients).

292
293
294 10. *Trial Procedures and Timing of Assessments*

295
296 a. Entry visit

297
298 At the entry visit, the protocol should specify the collection of baseline demographics, clinical
299 information, sputum specimen for evaluation and culture, and baseline laboratory tests, as
300 appropriate.

301
302 b. On-therapy and end-of-therapy visits

303
304 The protocol should specify an evaluation of patients during therapy and at the end of therapy
305 and should specify clinical and laboratory assessments for safety as appropriate.

306
307 c. Visits after completion of therapy

308
309 The protocol should specify evaluations for continued clinical response or resolution of
310 HABP/VABP and safety at approximately 7 to 14 days after patients complete antibacterial
311 therapy. Sponsors should assess and report mortality, including a mortality assessment at day
312 28.

313
314 11. *Statistical Considerations*

315
316 In general, sponsors should provide, before trial initiation, a detailed statistical analysis plan
317 stating the trial hypotheses and the analysis methods before trial initiation. The primary efficacy
318 analysis should be based on the difference between treatment groups in the proportions of
319 success on the primary outcome measure, assessing either noninferiority or superiority.

320

Contains Nonbinding Recommendations

a. Analysis populations

The following definitions apply to various analysis populations:

- Intent-to-treat (ITT) population — All randomized patients.
- Safety population — All patients who received at least one dose of drug during the trial.
- Microbiological intent-to-treat (micro-ITT) population — All randomized patients who have a baseline bacterial pathogen known to cause HABP/VABP that is susceptible to the investigational drug and active control, identified from an appropriate sputum or blood specimen.
- Per-protocol populations — Patients who are not lost to follow-up and adhere to trial procedures as specified in the protocol.
- Per-protocol microbiologically evaluable populations — Patients who are characterized in the per-protocol population and have a baseline bacterial pathogen identified as the cause of HABP/VABP.

Sponsors should discuss with the Agency the prespecified primary analysis population before initiating the trial. In general, it is acceptable to consider the ITT population as the primary analysis population. For antibacterial drugs with a narrow spectrum of activity (e.g., a drug active against a single genus and species of bacteria), the micro-ITT population will be considered the primary analysis population.

b. Noninferiority margins

Historical data support the appropriateness of noninferiority trials for HABP/VABP (see the Appendix). For example, with the use of a survival endpoint, a noninferiority margin of 10 percent can be supported by the historical evidence, which supports a reduction in mortality by effective therapy of about 20 percent. A 10 percent noninferiority margin supports a preservation of a meaningful fraction of that effect. If a noninferiority margin >10 percent is selected, sponsors should discuss the rationale and justification with the Agency.

c. Sample size considerations

In one example of a sample size calculation, approximately 268 patients per group is estimated for the ITT analysis population based on the rate of all-cause mortality of 15 percent in the test and control groups and a noninferiority margin of 10 percent. The trial will rule out greater than 10 percent inferiority of the investigational drug to the control drug (an upper bound of the two-sided 95 percent confidence interval for the difference in the rates of all-cause mortality of the control drug minus the investigational drug).

Contains Nonbinding Recommendations

365 C. Other Considerations

366

367 1. *Pharmacokinetic/Pharmacodynamic Considerations*

368

369 Sponsors should evaluate the PK/pharmacodynamic (PD) characteristics of the drug using in
370 vitro methods and animal models of infection. Sponsors should also consider the limitations of
371 such models before evaluating the antibacterial drug (Tessier et al. 2002; Gavaldà et al. 1997;
372 Legget 1999; Miyazaki et al. 1997; Silverman et al. 2005).

373

374 Integration of these PK/PD characteristics of the drug with the findings from phase 1 clinical
375 trials can assist identification of appropriate dosing regimens for evaluation in phase 2 and phase
376 3 clinical trials.¹³

377

378 Sponsors should obtain blood samples from patients in phase 2 and phase 3 clinical trials (sparse
379 sampling) to estimate drug exposure in each patient. Sponsors should perform an exposure-
380 response analysis for clinical outcomes, microbiologic outcomes, and clinically relevant adverse
381 events. If phase 3 trials include a previously unstudied specific population, such as patients with
382 renal or hepatic impairment, collecting plasma drug concentrations from those specific
383 populations can aid in determining necessary dose adjustments.

384

385 2. *Labeling Considerations*

386

387 Generally, the labeled indication should reflect the patient population (HABP, VABP, or
388 HABP/VABP) enrolled in the clinical trials.

389

¹³ See the guidance for industry *Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications* (April 2003) and the ICH guidance for industry *E4 Dose-Response Information to Support Drug Registration* (November 1994).

Contains Nonbinding Recommendations

REFERENCES

- 390
391
392 Álvarez-Lerma, F, J Insausti-Ordeñana, R Jordá-Marcos, E Maraví-Poma, A Torres-Martí, J
393 Nava, A Martínez-Pellús, M Palomar, and F Barcenilla and the Spanish Collaborative Group for
394 the Study of Severe Infections, 2001, Efficacy and Tolerability of Piperacillin/Tazobactam
395 Versus Ceftazidime in Association With Amikacin for Treatment of Nosocomial Pneumonia in
396 Intensive Care Patients: A Prospective, Randomized, Multicenter Trial, *Intensive Care Med*,
397 27:493–502.
398
399 Corneli, A, B Perry, D Collyar, JH Powers III, JJ Farley, SB Calvert, J Santiago, HK Donnelly, T
400 Swezey, CB Dombeck, C De Anda, VG Fowler Jr., and TL Holland, 2018, Assessment of the
401 Perceived Acceptability of an Early Enrollment Strategy Using Advance Consent in Health Care-
402 Associated Pneumonia, *JAMA Netw Open*, 1(8):e185816.
403 doi:10.1001/jamanetworkopen.2018.5816.
404
405 DerSimonian, R and N Laird, 1986, Meta-Analysis in Clinical Trials, *Control Clin Trials*,
406 7(3):177–188.
407
408 Fink, MP, DR Snyderman, MS Niederman, KV Leeper Jr., RH Johnson, SO Heard, RG
409 Wunderink, JW Caldwell, JJ Schentag, and GA Siami, 1994, Treatment of Severe Pneumonia in
410 Hospitalized Patients: Results of a Multicenter, Randomized, Double-Blind Trial Comparing
411 Intravenous Ciprofloxacin With Imipenem/Cilastatin, *Antimicrob Agents Chemother*,
412 38(3):547–557.
413
414 Gavaldà, J, JA Capdevila, B Almirante, J Otero, I Ruiz, M Laguarda, H Allende, E Crespo, C
415 Pigrau, and A Pahissa, 1997, Treatment of Experimental Pneumonia due to Penicillin-Resistant
416 *Streptococcus Pneumoniae* in Immunocompetent Rats, *Antimicrob Agents Chemother*,
417 41(4):795–801.
418
419 Kalil, AC, ML Metersky, M Klompas, J Muscedere, DA Sweeney, LB Palmer, LM Napolitano,
420 NP O’Grady, JG Bartlett, J Carratalà, AA El Solh, S Ewig, PD Fey, TM File Jr., MI Restrepo,
421 JA Roberts, GW Waterer, P Cruse, SL Knight, and JL Brozek, 2016, Management of Adults
422 With Hospital-Acquired and Ventilator-Associated Pneumonia: 2016 Clinical Practice
423 Guidelines by the Infectious Diseases Society of America and the American Thoracic Society,
424 *Clin Infect Dis*, 63(5):e61–e111, <https://doi.org/10.1093/cid/ciw353>.
425
426 Knaus WA, EA Draper, DP Wagner, and JE Zimmerman, 1985, APACHE II: a Severity of
427 Disease Classification System, *Crit Care Med*, 13(10):818–829.
428
429 Kollef, MH and S Ward, 1998, The Influence of Mini-BAL Cultures on Patient Outcomes:
430 Implications for the Antibiotic Management of Ventilator-Associated Pneumonia, *Chest*,
431 113(2):412–420.
432
433 Legget, J, 1999, Murine Models of Pneumonia Using Aerosol Infection, In: Zak O, Sande MA,
434 eds., *Handbook of Animal Models of Infections*: San Diego, Academic Press, 533–538.
435

Contains Nonbinding Recommendations

- 436 Luna, CM, P Aruj, MS Niederman, J Garzón, D Violi, A Prignoni, F Rios, S Baquero, and S
437 Gando, 2006, Appropriateness and Delay to Initiate Therapy in Ventilator-Associated
438 Pneumonia, *Eur Respir J*, 27:158–164.
439
- 440 Miyazaki, S, T Nunoya, T Matsumoto, K Tateda, and K Yamaguchi, 1997, New Murine Model
441 of Bronchopneumonia Due to Cell-Bound *Haemophilus Influenzae*, *J Infect Dis*, 175(1):205–
442 209.
443
- 444 Pertel, PE, P Bernardo, C Fogarty, P Matthews, R Northland, M Benvenuto, GM Thorne, SA
445 Luperchio, RD Arbeit, and J Alder, 2008, Effects of Prior Effective Therapy on the Efficacy of
446 Daptomycin and Ceftriaxone for the Treatment of Community-Acquired Pneumonia, *Clin Infect*
447 *Dis*, 46(8):1142–1151.
448
- 449 Rubinstein, E, SK Cammarata, TH Oliphant, and RG Wunderink, 2001, Linezolid (PNU-
450 100766) Versus Vancomycin in the Treatment of Hospitalized Patients With Nosocomial
451 Pneumonia: A Randomized, Double-Blind, Multicenter Study, *Clin Infect Dis*, 32(3):402–412.
452
- 453 Silverman, JA, LI Mortin, ADG VanPraagh, T Li, and J Alder, 2005, Inhibition of Daptomycin
454 by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact, *J Infect Dis*, 191(12):2149–
455 2152.
456
- 457 Tessier, PR, M-K Kim, W Zhou, D Xuan, C Li, M Ye, CH Nightingale, and DP Nicolau, 2002,
458 Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal
459 Pneumonia, *Antimicrob Agents Chemother*, 46(5):1425–1434.
460
- 461 Vincent J-L, A deMendonca, F Cantraine, R Moreno, J Takala, PM Suter, CL Sprung, F
462 Colardyn, and S Blecher, 1998, Use of the SOFA Score to Assess the Incidence of Organ
463 Dysfunction/Failure in Intensive Care Units: Results of a Multicenter, Prospective Study, *Crit*
464 *Care Med*, 26(11):1793–1800.
465
- 466 West, M, BR Boulanger, C Fogarty, A Tennenberg, B Wiesinger, M Oross, S-C Wu, C Fowler,
467 N Morgan, and JB Kahn, 2003, Levofloxacin Compared With Imipenem/Cilastatin Followed By
468 Ciprofloxacin in Adult Patients With Nosocomial Pneumonia: A Multicenter, Prospective,
469 Randomized, Open-Label Study, *Clin Ther*, 25(2):485–506.
470
- 471 Wunderink, RG, SK Cammarata, TH Oliphant, and MH Kollef, 2003, Continuation of a
472 Randomized, Double-Blind, Multicenter Study of Linezolid Versus Vancomycin in the
473 Treatment of Patients With Nosocomial Pneumonia, *Clin Ther*, 25(3):980–992.
474

APPENDIX

**Support for a Noninferiority Margin for Clinical Trials
Evaluating Antibacterial Drugs for Treatment of HABP/VABP**

The usual source of information about the effect of the control drug, the basis for specifying a noninferiority margin, is placebo-controlled trials. Such trials do not exist for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). This Appendix describes an approach to providing historical evidence of sensitivity to drug effect and support for the noninferiority margin by comparing trials using inadequate or delayed treatment and trials using effective antibacterial drug treatment.

A literature search identified seven trials that evaluated patients who had HABP/VABP. Two trials evaluated patients who received inadequate or delayed treatment and five trials were prospective, controlled trials of effective antibacterial drug treatment. Patients in the seven trials had similar baseline demographic characteristics. Clinical responses were not provided in a standardized or consistent manner in any of these trials, so only all-cause mortality was identified in these trials as a well-defined and reliable clinical endpoint. The all-cause mortality reporting time period for these evaluations was variable (e.g., 30 days after completion of therapy, 28 days after onset of HABP/VABP, 12 days after completion of therapy) or was not reported at all. Tables 1 and 2 provide the results of all-cause mortality observed in each arm of the trials.

Table 1. Nonrandomized Evaluations Involving Inadequate or Delayed Treatment in Hospitalized Patients With HABP/VABP

Trial	Number of Patients (% Ventilator-Associated)	Inadequate or Delayed Treatment All-Cause Mortality n/N (%)	Appropriate Treatment All-Cause Mortality n/N (%)
Kollef and Ward 1998	102* (100%)	31/51 (61%)	17/51 (33%)
Luna et al. 2006	76 (100%)	33/52 (64%)	7/24 (29%)

*The trial evaluated 130 patients who were receiving mechanical ventilation, 28 of whom did not have evidence to support a diagnosis of VABP.

A random effects meta-analysis (DerSimonian and Laird 1986) for the estimate of mortality in patients who received inadequate or delayed treatment was 62 percent (95 percent confidence interval, 52 percent to 71 percent). An all-cause mortality rate was lower in patients who received appropriate treatment in these nonrandomized trials.

Contains Nonbinding Recommendations

510 **Table 2. Prospective, Controlled Clinical Trials Using Effective Antibacterial Drug**
 511 **Therapy in Patients With HABP/VABP**

Trial	Number of Patients (% Ventilator- Associated)	Effective Treatment Group 1* All-Cause Mortality n/N (%)	Effective Treatment Group 2* All-Cause Mortality n/N (%)
Alvarez-Lerma et al. 2001	124 (85.5%)	P/T/A 27/88 (31%)	Cef/A 8/36 (22%)
Fink et al. 1994	402 (75.6%)	Imi 38/200 (19%)	Cip 43/202 (21%)
Rubinstein et al. 2001	396 (57.3%)	Lin/Az 36/203 (18%)	Van/Az 49/193 (25%)
West et al. 2003	438 (10.7%)	Imi/Cip 32/218 (15%)	Lev/Lev PO 38/220 (17%)
Wunderink et al. 2003	623 (50.6%)	Lin/Az 64/321 (20%)	Van/Az 61/302 (20%)

512 * The data in the table are presented by the treatment groups (1 and 2) for these active-controlled trials; A =
 513 amikacin; Cef = ceftazidime; Cip = ciprofloxacin; Imi = imipenam/cilastatin; Lev = levofloxacin; P/T =
 514 piperacillin/tazobactam; Lin = linezolid; Az = Aztreonam; Van = vancomycin.

515
 516
 517 The estimate of mortality based on a random effects meta-analysis (DerSimonian and Laird
 518 1986) in patients who received effective antibacterial drug treatment (all 10 treatment groups
 519 from the 5 trials) was 20 percent (95 percent confidence interval, 18 percent to 23 percent). The
 520 meta-analyses yielded a lower bound estimate of all-cause mortality for inadequate or delayed
 521 treatment of HABP/VABP of 52 percent and an upper bound estimate of all-cause mortality
 522 among effective antibacterial drug treatment of 23 percent. An estimate of the treatment effect
 523 of an antibacterial drug over inadequate or delayed treatment is approximately 29 percent (52
 524 percent *minus* 23 percent). Allowing for some uncertainty of the results from these
 525 nonrandomized comparisons, the Agency considers an acceptable effectiveness margin of the
 526 active-control drug relative to placebo (M₁) to be 20 percent. Therefore, the Agency considers a
 527 noninferiority margin (M₂) of 10 percent to be reasonable both clinically and statistically.
 528 Sponsors can discuss with the Agency the selection of a noninferiority margin that is greater than
 529 10 percent.